Review



tp 021  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress tp 021
    BCOR deficiency sensitizes cells to DHODH Inhibitors. ( A ) Heatmaps representing survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with increasing doses <t>of</t> <t>TP-021</t> (BCOR inhibitor) and brequinar, for 6 days ( n = 3 per line). Survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with working dose of TP-021 (10 µM) compared to DMSO, with increasing doses of brequinar, for each cell line, for 6 days (two-way ANOVA, n = 3; p < 0.0001****; p < 0.001***). ( B ) Survival fractions of OCI-AML2, OCI-AML3 and RPE1; transfected with siRNA and ± treated with brequinar 1 µM (two-way ANOVA, n = 3; p < 0.0001****). ( C ) Cell proliferation assay of RPE1 transfected with siRNA, ± treated with brequinar 1 µM (two-way ANOVA, n = 2; p < 0.0001****) with ( D ) associated pictures taken at 48 h (basic analyzer – Incucyte, 10x magnification). (E) SKM-1 (BCOR-mutated AML) was treated with increasing doses of DHODH inhibitors for 6 days (two-way ANOVA, n = 3; p < 0.0001****). ( F ) OCI-AML3 BCOR_WT , OCI-AML3 BCOR_KO.03 , OCI-AML3 BCOR_KO.17 and OCI-AML3 BCOR_KO.24 were treated for 6 days with increasing doses of 5 different DHODH inhibitors (two-way ANOVA, n = 3; p < 0.0001****, p < 0.001***, p < 0.01**, p < 0.05*, n.s = non-significant)
    Tp 021, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tp 021/product/MedChemExpress
    Average 94 stars, based on 2 article reviews
    tp 021 - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia"

    Article Title: BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia

    Journal: Annals of Hematology

    doi: 10.1007/s00277-026-06773-z

    BCOR deficiency sensitizes cells to DHODH Inhibitors. ( A ) Heatmaps representing survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with increasing doses of TP-021 (BCOR inhibitor) and brequinar, for 6 days ( n = 3 per line). Survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with working dose of TP-021 (10 µM) compared to DMSO, with increasing doses of brequinar, for each cell line, for 6 days (two-way ANOVA, n = 3; p < 0.0001****; p < 0.001***). ( B ) Survival fractions of OCI-AML2, OCI-AML3 and RPE1; transfected with siRNA and ± treated with brequinar 1 µM (two-way ANOVA, n = 3; p < 0.0001****). ( C ) Cell proliferation assay of RPE1 transfected with siRNA, ± treated with brequinar 1 µM (two-way ANOVA, n = 2; p < 0.0001****) with ( D ) associated pictures taken at 48 h (basic analyzer – Incucyte, 10x magnification). (E) SKM-1 (BCOR-mutated AML) was treated with increasing doses of DHODH inhibitors for 6 days (two-way ANOVA, n = 3; p < 0.0001****). ( F ) OCI-AML3 BCOR_WT , OCI-AML3 BCOR_KO.03 , OCI-AML3 BCOR_KO.17 and OCI-AML3 BCOR_KO.24 were treated for 6 days with increasing doses of 5 different DHODH inhibitors (two-way ANOVA, n = 3; p < 0.0001****, p < 0.001***, p < 0.01**, p < 0.05*, n.s = non-significant)
    Figure Legend Snippet: BCOR deficiency sensitizes cells to DHODH Inhibitors. ( A ) Heatmaps representing survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with increasing doses of TP-021 (BCOR inhibitor) and brequinar, for 6 days ( n = 3 per line). Survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with working dose of TP-021 (10 µM) compared to DMSO, with increasing doses of brequinar, for each cell line, for 6 days (two-way ANOVA, n = 3; p < 0.0001****; p < 0.001***). ( B ) Survival fractions of OCI-AML2, OCI-AML3 and RPE1; transfected with siRNA and ± treated with brequinar 1 µM (two-way ANOVA, n = 3; p < 0.0001****). ( C ) Cell proliferation assay of RPE1 transfected with siRNA, ± treated with brequinar 1 µM (two-way ANOVA, n = 2; p < 0.0001****) with ( D ) associated pictures taken at 48 h (basic analyzer – Incucyte, 10x magnification). (E) SKM-1 (BCOR-mutated AML) was treated with increasing doses of DHODH inhibitors for 6 days (two-way ANOVA, n = 3; p < 0.0001****). ( F ) OCI-AML3 BCOR_WT , OCI-AML3 BCOR_KO.03 , OCI-AML3 BCOR_KO.17 and OCI-AML3 BCOR_KO.24 were treated for 6 days with increasing doses of 5 different DHODH inhibitors (two-way ANOVA, n = 3; p < 0.0001****, p < 0.001***, p < 0.01**, p < 0.05*, n.s = non-significant)

    Techniques Used: Transfection, Proliferation Assay



    Similar Products

    tp 021  (MedChemExpress)
    94
    MedChemExpress tp 021
    BCOR deficiency sensitizes cells to DHODH Inhibitors. ( A ) Heatmaps representing survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with increasing doses <t>of</t> <t>TP-021</t> (BCOR inhibitor) and brequinar, for 6 days ( n = 3 per line). Survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with working dose of TP-021 (10 µM) compared to DMSO, with increasing doses of brequinar, for each cell line, for 6 days (two-way ANOVA, n = 3; p < 0.0001****; p < 0.001***). ( B ) Survival fractions of OCI-AML2, OCI-AML3 and RPE1; transfected with siRNA and ± treated with brequinar 1 µM (two-way ANOVA, n = 3; p < 0.0001****). ( C ) Cell proliferation assay of RPE1 transfected with siRNA, ± treated with brequinar 1 µM (two-way ANOVA, n = 2; p < 0.0001****) with ( D ) associated pictures taken at 48 h (basic analyzer – Incucyte, 10x magnification). (E) SKM-1 (BCOR-mutated AML) was treated with increasing doses of DHODH inhibitors for 6 days (two-way ANOVA, n = 3; p < 0.0001****). ( F ) OCI-AML3 BCOR_WT , OCI-AML3 BCOR_KO.03 , OCI-AML3 BCOR_KO.17 and OCI-AML3 BCOR_KO.24 were treated for 6 days with increasing doses of 5 different DHODH inhibitors (two-way ANOVA, n = 3; p < 0.0001****, p < 0.001***, p < 0.01**, p < 0.05*, n.s = non-significant)
    Tp 021, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tp 021/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    tp 021 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    BCOR deficiency sensitizes cells to DHODH Inhibitors. ( A ) Heatmaps representing survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with increasing doses of TP-021 (BCOR inhibitor) and brequinar, for 6 days ( n = 3 per line). Survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with working dose of TP-021 (10 µM) compared to DMSO, with increasing doses of brequinar, for each cell line, for 6 days (two-way ANOVA, n = 3; p < 0.0001****; p < 0.001***). ( B ) Survival fractions of OCI-AML2, OCI-AML3 and RPE1; transfected with siRNA and ± treated with brequinar 1 µM (two-way ANOVA, n = 3; p < 0.0001****). ( C ) Cell proliferation assay of RPE1 transfected with siRNA, ± treated with brequinar 1 µM (two-way ANOVA, n = 2; p < 0.0001****) with ( D ) associated pictures taken at 48 h (basic analyzer – Incucyte, 10x magnification). (E) SKM-1 (BCOR-mutated AML) was treated with increasing doses of DHODH inhibitors for 6 days (two-way ANOVA, n = 3; p < 0.0001****). ( F ) OCI-AML3 BCOR_WT , OCI-AML3 BCOR_KO.03 , OCI-AML3 BCOR_KO.17 and OCI-AML3 BCOR_KO.24 were treated for 6 days with increasing doses of 5 different DHODH inhibitors (two-way ANOVA, n = 3; p < 0.0001****, p < 0.001***, p < 0.01**, p < 0.05*, n.s = non-significant)

    Journal: Annals of Hematology

    Article Title: BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia

    doi: 10.1007/s00277-026-06773-z

    Figure Lengend Snippet: BCOR deficiency sensitizes cells to DHODH Inhibitors. ( A ) Heatmaps representing survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with increasing doses of TP-021 (BCOR inhibitor) and brequinar, for 6 days ( n = 3 per line). Survival fractions of OCI-AML2, OCI-AML3 and RPE1 treated with working dose of TP-021 (10 µM) compared to DMSO, with increasing doses of brequinar, for each cell line, for 6 days (two-way ANOVA, n = 3; p < 0.0001****; p < 0.001***). ( B ) Survival fractions of OCI-AML2, OCI-AML3 and RPE1; transfected with siRNA and ± treated with brequinar 1 µM (two-way ANOVA, n = 3; p < 0.0001****). ( C ) Cell proliferation assay of RPE1 transfected with siRNA, ± treated with brequinar 1 µM (two-way ANOVA, n = 2; p < 0.0001****) with ( D ) associated pictures taken at 48 h (basic analyzer – Incucyte, 10x magnification). (E) SKM-1 (BCOR-mutated AML) was treated with increasing doses of DHODH inhibitors for 6 days (two-way ANOVA, n = 3; p < 0.0001****). ( F ) OCI-AML3 BCOR_WT , OCI-AML3 BCOR_KO.03 , OCI-AML3 BCOR_KO.17 and OCI-AML3 BCOR_KO.24 were treated for 6 days with increasing doses of 5 different DHODH inhibitors (two-way ANOVA, n = 3; p < 0.0001****, p < 0.001***, p < 0.01**, p < 0.05*, n.s = non-significant)

    Article Snippet: For pharmacologic studies, cells were treated with brequinar (Cayman Chemical), TP-021, leflunomide, teriflunomide, AG-636, farudodstat, sparfosic acid (MedChemExpress), or 6-azauridine (Thermo Fisher).

    Techniques: Transfection, Proliferation Assay